1
|
Brulle-Soumare L, Bigot L, Mevel K, Le Ven E, Friboulet L, Besse B, Farace F, Judde JG, Cairo S, Loriot Y, Déas O. Abstract 3113: Molecular and pharmacological profiling of a novel prostate cancer-derived xenograft panel to identify resistance mechanisms and new therapeutic options. Cancer Res 2022. [DOI: 10.1158/1538-7445.am2022-3113] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Prostate Cancer (PCa) is the most frequently diagnosed cancer in men and remains one of the leading causes of cancer death worldwide. It is a highly heterogenous and complex disease, presenting serious challenges to preclinical drug development and biomedical research. Prostate normal development, growth and function, as well as most of its pathological drifts, are associated to androgen receptor (AR) pathway regulation. Most patients subjected to androgen deprivation therapy (ADT) respond well to the treatment, however they usually progress into intractable castration-resistant PCa (CRPC) within 2 to 3 years. Therefore, understanding the mechanisms of castration resistance underlying PCa progression is key to develop future therapies. Patient-Derived Xenografts (PDX) are mouse models that recapitulate the disease more faithfully than any other in vivo model in terms of histopathologic, genomic and metastatic features, facilitating the translation of preclinical results in the clinical setting. PCa PDXs are challenging to develop, and only few are available to the scientific community. This lack of relevant preclinical models is a major limitation in PCa research. In particular, the development of PCa PDX models from castration-resistant tumors to explore new treatments against CRPC is a requirement. To fill this gap, XenTech and Gustave Roussy Institute are collaborating to develop a panel of PCa PDX models. In the framework of the MATCH-R clinical trial (NCT02517892), in which patients with disease progression under treatment are enrolled and switched to new targeted therapy based on the genetic alterations identified in biopsies, 8 PCa PDXs have been developed from metastatic lesions biopsy. In addition, we developed a PCa PDX model from circulating tumor cells (CTCs) obtained by leukapheresis at diagnosis. These 9 models, plus 4 PCa PDXs previously developed at XenTech, increases our PCa PDX panel to 13 models. All models were characterized at molecular level by whole exome and RNA sequencing and pharmacologically for response to standards of care, physical castration and response to the androgen receptor inhibitor enzalutamide. This PDX collection is a valuable preclinical tool to identify pivotal mechanisms underlying acquired resistance to current therapies and develop novel treatment strategies against PCa and CRPC.
Citation Format: Laura Brulle-Soumare, Ludovic Bigot, Katell Mevel, Enora Le Ven, Luc Friboulet, Benjamin Besse, Françoise Farace, Jean Gabriel Judde, Stefano Cairo, Yohann Loriot, Olivier Déas. Molecular and pharmacological profiling of a novel prostate cancer-derived xenograft panel to identify resistance mechanisms and new therapeutic options [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 3113.
Collapse
|
2
|
Gaston J, Cheradame L, Legrier ME, Deas O, Judde JG, Goffin V, Cairo S. Abstract 2138: Functional evaluation of interferon/STAT1 pathway activation in response to genotoxic treatment. Cancer Res 2016. [DOI: 10.1158/1538-7445.am2016-2138] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Triple negative breast cancer (TNBC) accounts for approximately 15-25% of breast cancers at diagnosis, and is one of the most aggressive subtypes, with around 70% of patients that live free of disease 5 years post-diagnosis. One of the most reliable predictive markers of patient outcome is the pathological complete response (pCR), with no tumor cells detectable at histopathological level after neoadjuvant chemotherapy.
As pCR is observed in only about 20-30% of TNBC, it is mandatory to identify new therapeutic options to improve pCR rate upon neoadjuvant chemotherapy. The mechanisms of tumor resistance remain an unmet need in oncology. In a recent study, we used our breast cancer PDXs collection to tackle this question, and address the mechanisms of tumor response to treatment vs tumor recurrence. To do this we analyzed the gene expression profile of laser-microdissected residual tumor nodules interspersed in the murine stroma upon very efficient tumor response to Adriamycin/Cyclophosphamide (AC). When doing so, we identified several genes of the IFN/STAT1 pathway that were strongly over-expressed when compared to pre-treatment tumors. In this study, we investigated the mechanisms leading to IFN/STAT1 pathway activation following chemotherapy in tumor cells and we evaluated the functional involvement of the IFN/STAT1 signature as a whole or at single target gene level in residual tumor cell resistance to chemotherapy after genotoxic treatment.
To this aim, we set up an ex-vivo/in vitro assay to mimic induction of the IFN/STAT1 signature in tumor cells after genotoxic treatment. We identified cell lines and primary cultures from a patient-derived xenograft (PDX) that mimicked the in vivo situation, as only the cell lines that respond to genotoxic stress in vivo activated IFN/STAT1 pathway in response to genotoxic treatment in vitro. When exposed to conditioned medium collected from mafosfamide-treated cancer cells, these cells activated luciferase reporter genes harboring ISRE (interferon stimulated response elements) and GAS (gamma interferon activated sequence) response elements, suggesting active ligands of the IFN/STAT1 pathways were secreted. STAT1 or IFNAR1 gene silencing (siRNA) resulted in markedly attenuated gene signature expression after mafosfamide treatment. The addition of conditioned medium significantly reduced mafosfamide-induced cancer cell death suggesting that IFN/STAT1-related genes over-expression may ultimately have protective effect on cancer cell viability. Accordingly, the inhibition of several genes of the IFN/STAT pathway, or DNA sensors acting upstream, increased cell mortality when combined with genotoxic treatment and delayed colony formation.
Overall, this study supports the functional implication of IFN/STAT1-related genes in tumor resistance to genotoxic treatment.
Citation Format: Julie Gaston, Laura Cheradame, Marie-Emmanuelle Legrier, Olivier Deas, Jean Gabriel Judde, Vincent Goffin, Stefano Cairo. Functional evaluation of interferon/STAT1 pathway activation in response to genotoxic treatment. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 2138.
Collapse
|
3
|
Faugeroux V, Deas O, Michels J, Judde JG, Cairo S, Vielh P, Marty V, Billiot F, Ngocamus M, Besse B, Kannouche P, Farace F. Abstract 2256: Establishment and characterization of circulating tumor cell-derived xenografts in non-small cell lung cancer. Cancer Res 2016. [DOI: 10.1158/1538-7445.am2016-2256] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Low numbers of circulating tumor cells (CTCs) have so far limited the establishment of CTC-derived xenografts (CDXs) to improve our understanding of tumor progression, drug resistance mechanisms, and their biological properties. We report the establishment and the phenotypic and molecular characterization of one NSCLC CDX.
Blood samples (30 ml) were drawn from 49 NSCLC patients with advanced metastatic disease. CTCs were enriched by RosetteSep, embedded in matrigel, and implanted in the interscapular aspect of NSG mouse (Nod/Scid-IL2Rγ-/-). Mice were followed-up for one year according to ethical regulations. CDX tumours and CDX derived cell lines were phenotypically and molecularly characterized by immunofluorescence, immunohistochemistry, CGHarray, exome sequencing and transcriptome gene expression.
CTCs from one NSCLC patient with 750 CTCs detected by CellSearch gave rise to a tumor 5 months after initial murine injection. Histological analysis confirmed the human origin of the tumor and the presence of a poorly differentiated adenocarcinoma consistent with the patient's biopsy. Tumor was positive for EpCAM, EMA, CK8;18, and Ki67, and negative for vimentin. A fraction of cells (25%) from freshly dissociated tumors exhibited ALDH activity. CGH from CDX tumors at passage 1 and 2 shows multiple gene rearrangement, revealing a high degree of genomic instability. Transcriptome analysis of ALDH positive and negative cells is ongoing and should help of identifying a cancer stem cell gene expression signature. Whole-exome sequencing of CDX tumor is ongoing and will be compared to data obtained from single CTCs from the patient.
A cell line established in vitro from the CDX model grows in 3D clusters and is tumorigenic in mice. Interestingly, this cell line is positive for cytokeratins, EpCAM, E-cadherin, N-cadherin, vimentin, and expresses multiple cancer stem cell markers including CD166, CD24, CD133 and, ALDH activity. The cell line is hypotetraploid (about 70 chromosomes) and its CGH profile was similar to that of the CDX tumour, revealing a high level of genome instability. By investigating DNA replication process in this cell line, we found that it exhibits a spontaneous enhanced DNA damage signaling associated to an accumulation of DNA double strand breaks mainly in S phase strongly suggesting that the CDX-derived cell line displays hallmarks on replication stress that could explain, at least partially, the genomic instability in the cells.
We report a low success rate in the establishment of NSCLC CDX (2%). However one NSCLC CDX model harboring cancer stem cell properties and deficiency of DNA replication maintenance was established. Ongoing work to identify a cancer stem cell signature and characteristics replication stress markers in this CDX model will be presented. This NSCLC CDX model will be useful to test drugs targeting these alterations in vivo and improve our knowledge of drug resistance.
Citation Format: Vincent Faugeroux, Olivier Deas, Judith Michels, Jean Gabriel Judde, Stefano Cairo, Philippe Vielh, Virginie Marty, Fanny Billiot, Maud Ngocamus, Benjamin Besse, Patricia Kannouche, Françoise Farace. Establishment and characterization of circulating tumor cell-derived xenografts in non-small cell lung cancer. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 2256.
Collapse
|
4
|
Lacoste V, Judde JG, Brière J, Tulliez M, Garin B, Kassa-Kelembho E, Morvan J, Couppié P, Clyti E, Forteza Vila J, Rio B, Delmer A, Mauclère P, Gessain A. Molecular epidemiology of human herpesvirus 8 in africa: both B and A5 K1 genotypes, as well as the M and P genotypes of K14.1/K15 loci, are frequent and widespread. Virology 2000; 278:60-74. [PMID: 11112482 DOI: 10.1006/viro.2000.0629] [Citation(s) in RCA: 73] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
We have studied 52 new HHV8 strains by sequencing the complete hypervariable K1 gene and genotyping the K14.1/K15 loci located at both sides, respectively, of the viral genome. The samples originated from 49 patients with Kaposi's sarcoma (KS; 32 patients), multicentric Castleman's disease (MCD; 12 patients), or primary effusion lymphoma (PEL; 5 patients). Among these patients, 32 were of African origin (West and Central African countries and Creoles from French Guiana) and the 17 others were mostly French homosexuals. Comprehensive phylogenetic studies allowed the identification of distinct groups within the three already known main subtypes. Interestingly, two new sequences that did not cluster within a known subtype or group could be considered as prototypes of early/ancient variants of the C subtype and A/C set, respectively. Among the 32 African strains, the majority were either of the B subtype (13 cases) or of the A5 group (11 cases), indicating that this latter genotype is frequent and widespread in Africa. In contrast, a subtype C strain infected most of the 17 other patients. PCR-based genotyping of the K14.1/K15 loci revealed an overall predominance of P subtype, except in the A5 and B K1 groups, in which the P and M alleles were equally represented. The implications of these data on the evolution and spread of HHV8 among human African populations are discussed.
Collapse
Affiliation(s)
- V Lacoste
- Unité d'Oncologie Virale, Département du SIDA et des Rétrovirus, Institut Pasteur, 25-28 rue du Dr. Roux, Paris Cedex 15, 75724, France
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
5
|
Lacoste V, Judde JG, Bestett G, Cadranel J, Antoine M, Valensi F, Delabesse E, Macintyre E, Gessain A. Virological and molecular characterisation of a new B lymphoid cell line, established from an AIDS patient with primary effusion lymphoma, harbouring both KSHV/HHV8 and EBV viruses. Leuk Lymphoma 2000; 38:401-9. [PMID: 10830748 DOI: 10.3109/10428190009087032] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
We report here a new case of primary effusion lymphoma (PEL), occurring in a French homosexual HIV-1 infected male with a pericardial, pleural and mesenteric tumour dissemination, and the establishment from his pleural effusion of a new cell line, Cra-BCBL, dually infected by EBV and KSHV/HHV8. Cra-BCBL cells are of B-cell origin as judged by their clonal immunoglobulin heavy chain (IgH) gene rearrangement, identical to that of the parental tumour. Both the cell line and the lymphoma cells expressed CD38 and CD45 antigens but no classical B-cell or T-cell lineage-restricted antigens. Cra-BCBL harbours a type I EBV virus, expressing a latency type II. Expression of KSHV/HHV8 ORF72 and ORF75 was detected by RT/PCR. In addition, KSHV lytic replication could be induced by treatment by n-butyrate. An equivalent and high copy number of KSHV genomes (20 to 200 copies by cell) was detected both in the primary tumour cells and in the cell line. Southern blot (SB) analysis of EBV terminal repeats (TR) displayed the same unique band in the cell line DNA and in the original tumour cells, consistent with a monoclonal infection of EBV. Furthermore, SB analysis of KSHV/HHV8 TR revealed the same hybridisation pattern between Cra-BCBL and the effusion cells, with a common band at around 30-40 kb corresponding to the fused termini of the viral episomes and a 5 Kb rearranged fragment. The new cell line characterised here could be a useful model to study interactions between two human herpes viruses and their contribution to lymphomagenesis.
Collapse
MESH Headings
- Adult
- B-Lymphocytes/metabolism
- B-Lymphocytes/pathology
- B-Lymphocytes/virology
- Cell Transformation, Viral
- DNA, Neoplasm/genetics
- DNA, Viral/genetics
- DNA, Viral/isolation & purification
- Epstein-Barr Virus Infections/complications
- Epstein-Barr Virus Infections/pathology
- Epstein-Barr Virus Infections/virology
- Gene Expression Regulation, Neoplastic
- Gene Expression Regulation, Viral
- Gene Rearrangement, B-Lymphocyte
- Genes, Immunoglobulin
- Herpesviridae Infections/complications
- Herpesviridae Infections/pathology
- Herpesviridae Infections/virology
- Herpesvirus 4, Human/isolation & purification
- Herpesvirus 4, Human/physiology
- Herpesvirus 8, Human/isolation & purification
- Herpesvirus 8, Human/physiology
- Humans
- Immunophenotyping
- Lymphoma, AIDS-Related/pathology
- Lymphoma, AIDS-Related/virology
- Lymphoma, B-Cell/pathology
- Lymphoma, B-Cell/virology
- Male
- Neoplastic Stem Cells/metabolism
- Neoplastic Stem Cells/pathology
- Neoplastic Stem Cells/virology
- Open Reading Frames
- Pleural Effusion, Malignant/pathology
- Pleural Effusion, Malignant/virology
- Reverse Transcriptase Polymerase Chain Reaction
- Tumor Cells, Cultured/metabolism
- Tumor Cells, Cultured/virology
- Tumor Virus Infections/complications
- Tumor Virus Infections/pathology
- Tumor Virus Infections/virology
- Virus Replication
Collapse
Affiliation(s)
- V Lacoste
- Département SIDA et Rétrovirus, Institut Pasteur, Paris, France
| | | | | | | | | | | | | | | | | |
Collapse
|
6
|
Judde JG, Lacoste V, Brière J, Kassa-Kelembho E, Clyti E, Couppié P, Buchrieser C, Tulliez M, Morvan J, Gessain A. Monoclonality or oligoclonality of human herpesvirus 8 terminal repeat sequences in Kaposi's sarcoma and other diseases. J Natl Cancer Inst 2000; 92:729-36. [PMID: 10793109 DOI: 10.1093/jnci/92.9.729] [Citation(s) in RCA: 99] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
BACKGROUND Infection with human herpesvirus 8 (HHV8), also termed Kaposi's sarcoma (KS)-associated herpesvirus, is associated with all forms of KS, with primary effusion lymphoma (PEL), and with some forms of multicentric Castleman's disease (MCD), but the pathogenic role of HHV8 in these tumors and the clonal nature of KS are still unclear. The purpose of this study was to examine whether the number of terminal repeats (TRs) contained in the fused TR region of HHV8 could be used as a marker of clonality in HHV8-associated tumors. METHODS Pulsed-field gel electrophoresis (PFGE) and multiple-probe Southern blot analysis of the HHV8 TR region were performed on high-molecular-weight DNA obtained from tumoral KS, PEL, and MCD lesions. RESULTS These analysis showed that the fused TR region contains a large but variable number of TR units (ranging from 16 to 75) and that the viral genome is present as extrachromosomal circular DNA in these tumors in vivo, with occasional ladders of heterogeneous linear termini reflecting lytic replication. All PEL tumors and PEL-derived cell lines as well as some KS tumors contained monoclonal or oligoclonal fused TR fragments; however, the TR region appeared polyclonal in MCD tumors and in a few KS lesions. CONCLUSION Several KS and PEL lesions are monoclonal expansions of a single infected cell, suggesting that HHV8 infection precedes tumor growth and thus supporting an etiologic role of latent HHV8 in these proliferations. Our finding that nodular KS lesions display all possible patterns of clonality supports the model according to which KS begins as a polyclonal disease with subsequent evolution to a monoclonal process.
Collapse
Affiliation(s)
- J G Judde
- Unité d'Oncologie Virale, Département des Rétrovirus, Institut Pasteur, Paris, France.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
7
|
Lacoste V, Kadyrova E, Chistiakova I, Gurtsevitch V, Judde JG, Gessain A. Molecular characterization of Kaposi's sarcoma-associated herpesvirus/human herpesvirus-8 strains from Russia. J Gen Virol 2000; 81:1217-22. [PMID: 10769063 DOI: 10.1099/0022-1317-81-5-1217] [Citation(s) in RCA: 26] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022] Open
Abstract
We report the molecular characterization, with subtyping of both K1 and K14.1/K15 genomic regions, of seven new human herpesvirus-8 (HHV-8) strains from Russian patients with classical Kaposi's sarcoma. Phylogenetic studies, based on the complete K1 gene/protein analysis, indicate that six of these strains belong to the A subtype, with one belonging to the A4 group and exhibiting a unique deletion of 19 amino acids in the VR2 region at position 186-204. PCR-based studies of the K14.1/K15 genomic region indicate that four of the new strains were of the M subtype while three belonged to the P subtype. Our study indicates an important genetic diversity of the HHV-8 strains currently present in Russia, including a new peculiar strain possessing a unique deletion in the VR2 segment, and confirms the absence of correlation between the K1 and K14.1/K15 molecular subtypes, as M and P genotypes can be observed in the A K1 subtype.
Collapse
Affiliation(s)
- V Lacoste
- Unité d'Oncologie Virale, Département du SIDA et des Rétrovirus, Institut Pasteur, 28, rue du Dr Roux, 75724 Paris Cedex 15, France
| | | | | | | | | | | |
Collapse
|
8
|
Gutiérrez MI, Raj A, Spangler G, Sharma A, Hussain A, Judde JG, Tsao SW, Yuen PW, Joab I, Magrath IT, Bhatia K. Sequence variations in EBNA-1 may dictate restriction of tissue distribution of Epstein-Barr virus in normal and tumour cells. J Gen Virol 1997; 78 ( Pt 7):1663-70. [PMID: 9225043 DOI: 10.1099/0022-1317-78-7-1663] [Citation(s) in RCA: 65] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023] Open
Abstract
In seropositive individuals Epstein-Barr virus (EBV) establishes a virus reservoir in peripheral blood lymphocytes (PBLs). Transmission from one individual to another occurs via saliva due to a lytic (virion productive) phase of infection in the oropharynx. EBNA-1 is responsible for maintaining viral episomes in the host cell and could, therefore, also affect the persistence of the virus in different cell lineages. Based on sequence analysis of EBNA-1 we now demonstrate that (i) in addition to the prototype EBNA-1 (identical to the B95.8 virus EBNA-1), EBV in normal individuals encompasses multiple EBNA-1 subtypes, both in PBLs and in oral secretions; (ii) although EBV with prototype EBNA-1 is the predominant virus in normal individuals, it is very rarely associated with either nasopharyngeal carcinoma (NPC) or Burkitt's lymphoma (BL); (iii) EBV with an EBNA-1 subtype (V-val) frequently associated with NPC is also selectively detected in oral secretions and not in PBLs; (iv) EBV with the EBNA-1 subtype V-pro is restricted to PBLs, while a mutated version of this subtype is present in BL, but not in NPC. These findings suggest that the variations in EBNA-1 may be relevant to the ability of EBV to persist in different cell types, and hence relevant to its oncogenic potential.
Collapse
Affiliation(s)
- M I Gutiérrez
- Lymphoma Biology Section, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892-1928, USA
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
9
|
Bhatia K, Raj A, Guitierrez MI, Judde JG, Spangler G, Venkatesh H, Magrath IT. Variation in the sequence of Epstein Barr virus nuclear antigen 1 in normal peripheral blood lymphocytes and in Burkitt's lymphomas. Oncogene 1996; 13:177-81. [PMID: 8700544] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/01/2023]
Abstract
We have examined sequence variations in the EBNA-1 protein of EBV in normal peripheral blood lymphocytes (PBL) and Burkitt's lymphomas (BL). We find two EBNA-1 strains P (prototype) and V (variant) which differ by 15 amino acids. Each strain has two subtypes defined by the amino acid at position 487 (P-ala, P-thr, V-pro and V-leu). In PBLs from 32 normal individuals, up to three of these subtypes were found in each sample, but the V strain did not occur in the absence of P strain viruses, nor was the V-leu subtype ever observed in normal PBL. In BLs only a single subtype was observed in each tumor. The P-thr and V-leu subtypes were more frequently seen than the P-ala and V-pro subtypes, which occurred in only two and one of the 36 tumor samples respectively. The P-thr was the most commonly observed subtype in peripheral blood of both American and African lymphocytes as well as in African tumors. However, in 11 of 12 American tumors, the EBNA-1 subtype was V-leu. These data indicate that some EBNA-1 subtypes are more likely to lead to oncogenesis, and one subtype, V-leu, appears only to occur in tumors.
Collapse
Affiliation(s)
- K Bhatia
- Lymphoma Biology Section, Pediatric Branch, National Cancer Institute, NIH, Bethesda, MD, USA
| | | | | | | | | | | | | |
Collapse
|
10
|
Abstract
To target expression of toxic genes to Epstein-Barr virus (EBV)-associated tumor cells, we have developed an EBV-driven enzyme prodrug system (EDEPS) that takes advantage of the trans-activating properties of EBNA1, a latent protein expressed in all EBV-containing cells, to direct expression of cytosine deaminase (CD) at high levels in those cells only. Plasmids were constructed in which the CD gene or a luciferase reporter gene were cloned downstream of the herpes simplex virus thymidine kinase (tk) promoter and the family of repeats (FR) sequence from the oriP region of EBV. Analysis of luciferase activity after transient transfection into a panel of EBV-negative or -positive human cell lines showed that the presence of the FR element enhanced transcription from the tk promoter in all EBV-positive cell lines, whereas transcription from tk was repressed in all EBV-negative cell lines, including B, T, and fibroblast cell lines. In clonogenicity assays following transfection with the CD vector, the presence of 5-fluorocytosine (5-FC) in the culture medium completely abolished cell growth in EBV-positive cell lines, but did not affect the growth of EBV-negative cell lines. This vector system should have wide applicability in that it allows targeted expression of any gene of interest to tumors that carry EBV, irrespective of the role EBV plays in their pathogenesis.
Collapse
Affiliation(s)
- J G Judde
- Lymphoma Biology Section, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
| | | | | | | |
Collapse
|
11
|
Gutiérrez MI, Judde JG, Magrath IT, Bhatia KG. Switching viral latency to viral lysis: a novel therapeutic approach for Epstein-Barr virus-associated neoplasia. Cancer Res 1996; 56:969-72. [PMID: 8640787] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/01/2023]
Abstract
We describe an EBV-driven lytic system (LySED) that can be used to specifically target therapy to EBV- containing tumors. This system takes advantage of the transactivating properties of EBNA-1, a latency protein expressed in all EBV-containing cells, to drive the expression of Zta, a gene sufficient for inducing the EBV lytic cycle. Thus, EBV provides both the target and the executor for mediating tumor-specific cell death, markedly increasing the specificity of the system. Transfection of EBV-positive cell lines with the LySED construct resulted in a switch to lytic cycle and subsequent cell death, even in the presence of an inhibitor of EBV thymidine kinase (acyclovir) without an increase in virion production. In contrast, growth of EBV-negative B-cell lines was not affected.
Collapse
Affiliation(s)
- M I Gutiérrez
- Lymphoma Biology Section, Pediatric Branch, National Cancer Institute, NIH, Bethesda, Maryland, 20892-1928, USA
| | | | | | | |
Collapse
|
12
|
Kalebic T, Judde JG, Velez-Yanguas M, Knutsen T, Helman LJ. Metastatic human rhabdomyosarcoma: molecular, cellular and cytogenetic analysis of a novel cellular model. Invasion Metastasis 1996; 16:83-96. [PMID: 9030243] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
A new human metastatic rhabdomyosarcoma (RMS) model was established and analyzed for a number of biologic, cytogenetic and molecular parameters. Consistent with previous studies, the metastatic capacity of different RMS cell variants did not correlate with their tumorigenic or proliferative capacities. Interestingly, a highly metastatic variant was diploid, while a nonmetastatic variant was tetraploid, which parallels previous clinical observations. Genes whose expression had been found to be associated with either low- or high-metastatic capacity in carcinoma or melanoma did not show a similar association with different metastatic variants of RMS, derived from a mesenchymal tumor. We also found, in transient reporter gene assays, that several promoters had higher transcriptional activity in highly metastatic than in nonmetastatic RMS cell variants. This novel human RMS metastatic model may be instrumental for a better understanding of the regulatory pathways that control the metastatic phenotype of tumors of mesenchymal origin.
Collapse
Affiliation(s)
- T Kalebic
- Molecular Oncology Section, National Cancer Institute, Rockville Pike, Bethesda, Md 20892, USA
| | | | | | | | | |
Collapse
|
13
|
Bhatia K, Fan S, Spangler G, Weintraub M, O'Connor PM, Judde JG, Magrath I. A mutant p21 cyclin-dependent kinase inhibitor isolated from a Burkitt's lymphoma. Cancer Res 1995; 55:1431-5. [PMID: 7882347] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
Abstract
The growth arrest mediated by p53 is caused at least in part by the p53 mediated expression of p21 (p21waf1/Cip1). Since only one-third of primary Burkitt's lymphomas (BL) demonstrate mutations in the p53 gene, we examined the structural integrity of the p21 coding region by single-strand conformational polymorphism and DNA sequence analysis to determine the extent to which this gene is mutated in BL. Of 34 BLs analyzed, a frequent change (38%) at codon 31 that replaced Ser with Arg was found in 13 samples, 10 of which were from Africa. This change at codon 31 is also detected in peripheral blood DNA from normal subjects and may thus represent a polymorphism. One BL cell line, DH978, carried a change at codon 63: Phe to Leu. This mutation was heterozygous, and both the wild-type and the mutated p21 mRNA were expressed in the tumor cell line. By transfection experiments, the mutant p21 was less efficient in suppressing clonogenicity than wild-type p21. To our knowledge, this is the only mutation described in p21. The availability of this mutant p21 should further help in functional studies of p21.
Collapse
Affiliation(s)
- K Bhatia
- Lymphoma Biology Section, National Cancer Institute, NIH, Bethesda, Maryland 20892
| | | | | | | | | | | | | |
Collapse
|
14
|
Jain VK, Judde JG, Max EE, Magrath IT. Variable IgH chain enhancer activity in Burkitt's lymphomas suggests an additional, direct mechanism of c-myc deregulation. J Immunol 1993; 150:5418-28. [PMID: 8515068] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/31/2023]
Abstract
The deregulation of the c-myc gene in small non-cleaved cell lymphomas (SNCL) with 8;14 translocations is thought to be due to the juxtaposition of this gene with the IgH chain locus, but exactly how the Ig locus contributes to the deregulation is unclear. One widely considered hypothesis is that Ig gene enhancers, when moved near c-myc, might stimulate inappropriate transcription of this gene. To evaluate this hypothesis, we have tested the ability of the two known H chain enhancers, the JH-C mu intronic enhancer and the 3' alpha enhancer, to support transcription from c-myc promoters, by using transient transfection assays in a panel of 32 SNCL cell lines with 8;14 translocations. The activity of the JH-C mu intronic enhancer varied widely among the cell lines tested and correlated with the presence of nuclear factors binding to the E4/octamer regions of the enhancer. The 3' alpha enhancer was much less active than the intronic enhancer in all of our cell lines and seems unlikely to account for the c-myc deregulation (although the enhancer we tested was from the rat, because the human homologue is unidentified at present). A marked difference was also seen in the ability of individual cell lines to support transcription from the unenhanced c-myc constructs. Cell lines supporting the lowest enhancer activity tended to support the highest level of transcription from unenhanced c-myc promoters. The differences in transcription from c-myc promoters were confirmed by stably transfecting constructs containing c-myc promoters in SNCL cell lines. Our data strongly suggest that the importance of Ig enhancers for c-myc deregulation varies markedly in different cell lines and that, for many, trans-acting regulators of the c-myc promoters are as important or more important, than Ig enhancers in the deregulation of the c-myc gene.
Collapse
Affiliation(s)
- V K Jain
- Pediatric Branch, National Cancer Institute, Bethesda, MD 20892
| | | | | | | |
Collapse
|
15
|
Jain VK, Judde JG, Max EE, Magrath IT. Variable IgH chain enhancer activity in Burkitt's lymphomas suggests an additional, direct mechanism of c-myc deregulation. The Journal of Immunology 1993. [DOI: 10.4049/jimmunol.150.12.5418] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Abstract
Abstract
The deregulation of the c-myc gene in small non-cleaved cell lymphomas (SNCL) with 8;14 translocations is thought to be due to the juxtaposition of this gene with the IgH chain locus, but exactly how the Ig locus contributes to the deregulation is unclear. One widely considered hypothesis is that Ig gene enhancers, when moved near c-myc, might stimulate inappropriate transcription of this gene. To evaluate this hypothesis, we have tested the ability of the two known H chain enhancers, the JH-C mu intronic enhancer and the 3' alpha enhancer, to support transcription from c-myc promoters, by using transient transfection assays in a panel of 32 SNCL cell lines with 8;14 translocations. The activity of the JH-C mu intronic enhancer varied widely among the cell lines tested and correlated with the presence of nuclear factors binding to the E4/octamer regions of the enhancer. The 3' alpha enhancer was much less active than the intronic enhancer in all of our cell lines and seems unlikely to account for the c-myc deregulation (although the enhancer we tested was from the rat, because the human homologue is unidentified at present). A marked difference was also seen in the ability of individual cell lines to support transcription from the unenhanced c-myc constructs. Cell lines supporting the lowest enhancer activity tended to support the highest level of transcription from unenhanced c-myc promoters. The differences in transcription from c-myc promoters were confirmed by stably transfecting constructs containing c-myc promoters in SNCL cell lines. Our data strongly suggest that the importance of Ig enhancers for c-myc deregulation varies markedly in different cell lines and that, for many, trans-acting regulators of the c-myc promoters are as important or more important, than Ig enhancers in the deregulation of the c-myc gene.
Collapse
Affiliation(s)
- V K Jain
- Pediatric Branch, National Cancer Institute, Bethesda, MD 20892
| | - J G Judde
- Pediatric Branch, National Cancer Institute, Bethesda, MD 20892
| | - E E Max
- Pediatric Branch, National Cancer Institute, Bethesda, MD 20892
| | - I T Magrath
- Pediatric Branch, National Cancer Institute, Bethesda, MD 20892
| |
Collapse
|
16
|
Judde JG, Max EE. Characterization of the human immunoglobulin kappa gene 3' enhancer: functional importance of three motifs that demonstrate B-cell-specific in vivo footprints. Mol Cell Biol 1992; 12:5206-16. [PMID: 1406692 PMCID: PMC360454 DOI: 10.1128/mcb.12.11.5206-5216.1992] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022] Open
Abstract
Using a combination of in vivo footprinting and site-directed mutagenesis, we have functionally characterized an enhancer located 12 kb downstream of the human immunoglobulin kappa constant-region gene. The core enhancer region is highly homologous to the murine 3' kappa enhancer. However, in addition to two regulatory elements homologous to the functional motifs of the murine enhancer, we find a third positive regulatory element in the human enhancer. This element is associated with an 11/12-bp direct repeat (DR) that is well conserved in the murine locus but was not recognized as functionally important in the murine enhancer. Mutation of any of the three motifs of the human enhancer decreases its activity to 3 to 20% of the wild-type level, indicating cooperative interaction between these elements. The DR motif does not resemble any known enhancer element and does not appear to function as a transcriptional activator on its own when present in multiple copies. Interestingly, nuclear extracts from both B- and T-cell lines contain factors binding to DR in vitro, but in vivo footprinting shows no evidence of protein-DNA binding in the T-cell line. This finding suggests that an additional regulatory mechanism, such as the effect of chromatin configuration on accessibility, may be involved in the B-cell-restricted activity of the human 3' kappa enhancer.
Collapse
Affiliation(s)
- J G Judde
- Laboratory of Molecular Immunology, Food and Drug Administration, Bethesda, Maryland 20892
| | | |
Collapse
|
17
|
Judde JG, Ellis M, Frost P. Biochemical analysis of the role of transmethylation in the methionine dependence of tumor cells. Cancer Res 1989; 49:4859-65. [PMID: 2503245] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Abstract
The effects on methionine metabolism of the substitution of homocysteine for methionine in vitro were investigated in normal and tumor cell lines differing in their ability to utilize homocysteine for growth. The major finding of this study was that methionine-independent (Met-Indep) cell lines had much lower basal transmethylation rates than methionine-dependent (Met-Dep) cell lines. This was particularly evident in the parent SP1 cell line and its Met-Indep revertant, SP1-R. SP1-R compensated for a lack of methionine by reducing both its transmethylation and growth rates. An analysis of other potential differences in methionine metabolism between Met-Dep and Met-Indep cell lines failed to demonstrate any consistent abnormalities in all but the absolutely Met-Dep MDAY-D2 cell line. Thus, protein, S-adenosylmethionine, and polyamine synthesis were the same in Met-Dep and Met-Indep cell lines. These results indicate that the major regulatory step in determining the Met-Dep phenotype is an inherent increase in the rate of transmethylation reactions. Cell lines with high basal transmethylation rates cannot compensate for a relative deficiency of methionine and either cease growing (MDAY-D2) or generate revertants (SP1-R) for which the basal rate of transmethylation is considerably reduced.
Collapse
Affiliation(s)
- J G Judde
- Department of Cell Biology, University of Texas M. D. Anderson Cancer Center, Houston, 77030
| | | | | |
Collapse
|
18
|
Abstract
The stability of mixed tumor cell populations has been described in terms of phenotypic characteristics such as metastatic potential, immunogenicity, and drug resistance. We have extended these analyses to the molecular level in a model that uses transfection of the hemagglutinin antigen (HA) gene of influenza virus into murine CT-26 colorectal carcinoma cells. Transfection was followed by fluorescence-activated cell sorting (FACS) to select a parent population with expression of high levels of HA. We characterized this population (FACS-3) and four derived clones (5, 6, 9, and 18) over time with regard to phenotypic characteristics: immunogenicity and cross-protection against tumor challenge, cell surface expression of HA, evidence of HA gene amplification, and levels of HA mRNA. During 6 months in culture, the FACS-3 parent cells remained stable, but the individual clones varied for all of the parameters assessed. Among the clones, all possible molecular variations occurred, including changes in HA gene copy number (increased in clone 5 and decreased in clone 18), gene rearrangement (clone 5), decrease in HA mRNA (clones 6, 9, and 18), increase in HA mRNA (clone 5), and an abnormality in translational control or a posttranslational error. In all cases, the molecular changes correlated with cell surface HA expression, immunogenicity, and cross-protective potential. We conclude that in vitro clonal interactions play a role in stabilizing heterogeneity in this system. These studies show that even in the absence of selection, clonal interactions may alter the phenotype of tumors by increasing malignant progression or impeding tumor growth.
Collapse
Affiliation(s)
- T Itaya
- Department of Cell Biology, University of Texas, M.D. Anderson Cancer Center, Houston 77030
| | | | | | | |
Collapse
|
19
|
Judde JG, Frost P. Patterns of methionine auxotrophy in normal and neoplastic cells: the methionine independence of lymphocyte mitogenesis and low frequency of the methionine-dependent phenotype in human tumors. Cancer Res 1988; 48:6775-9. [PMID: 3180086] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/04/2023]
Abstract
Seven murine and 17 human tumor-derived cell lines were tested for their ability to grow in methionine-free medium containing the methionine precursor homocysteine. Three murine tumors, SP1, MDAY-D2, and L1210, failed to grow in this medium and were therefore methionine dependent (Met-Dep). In contrast, all human tumors, including 8 recently established cell lines, were methionine independent (Met-Indep). Concanavalin A-induced lymphocyte mitogenesis was also Met-Indep but required 3 to 4 times the amount of homocysteine needed for the growth of normal fibroblasts or Met-Indep tumors. In addition, lymphocyte mitogenesis was also supported by exogenous 5'-methylthioadenosine, another methionine precursor formed during polyamine synthesis. In contrast, Met-Dep tumors did not respond to increasing homocysteine concentration, nor was their growth supported by 5'-methylthioadenosine. These findings demonstrate that Met-Dep can occur by varied mechanisms relating to such parameters as homocysteine concentration and the ability of cells to generate Met-Indep revertants or to grow in 5'-methylthioadenosine. In general, we found the Met-Dep phenotype to be more common in murine tumor cells and to occur infrequently in human tumors. This may imply a species difference in methionine metabolism.
Collapse
Affiliation(s)
- J G Judde
- Department of Cell Biology, University of Texas, M.D. Anderson Cancer Center, Houston 77030
| | | |
Collapse
|
20
|
Judde JG, Breillout F, Clemenceau C, Poupon MF, Jasmin C. Inhibition of rat natural killer cell function by carcinogenic nickel compounds: preventive action of manganese. J Natl Cancer Inst 1987; 78:1185-90. [PMID: 2438444] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022] Open
Abstract
The effects of carcinogenic nickel [(Ni) CAS: 7440-02-0] and Ni compounds on the natural killer (NK) cell activity of rat peripheral blood mononuclear cells (PBMCs) were studied. Rhabdomyosarcomas were locally induced by one im injection of Ni or Ni subsulfide [(Ni3S2) CAS: 12035-72-2] dust in the hind leg of WAG rats. A weakly tumorigenic dose of 5 mg Ni3S2 (tumor incidence, 2%) induced a transient decrease of PBMC NK activity against YAC-1 cells in vitro (from the 17th to the 23d wk after Ni3S2 inoculation), which could be restored by in vivo injections of partially purified rat fibroblastic interferon (IFN). Injection of 20 mg Ni (tumor incidence, 47.5%) produced a long-lasting depression of NK cell activity (from the 8th to the 23d wk). In vivo chronic IFN treatment of the Ni-injected rats neither restored NK cell activity nor affected the tumor incidence. However, NK cells of Ni-treated animals responded normally to IFN in vitro. Prospective analysis of individual NK cell responses showed that a persistent depression of basal NK cell activity was restricted to rats that subsequently developed a tumor. In these animals the time between carcinogen treatment and clinical detection of the primary tumor was positively correlated with the mean level of NK cell activity (3-4 determinations/rat). Admixture of manganese to Ni inhibited the development of tumors and also prevented the depression of NK cell activity produced by Ni alone. Noncarcinogenic Ni oxide stimulated NK cell activity. These results point out the possible involvement of NK cells in resistance to Ni-induced carcinogenesis.
Collapse
|
21
|
Soubrane C, Jacobs C, Jacquillat C, Dubois M, Poupon MF, Judde JG, Maral J, Beaufils H, Jaudon MC. Influence of the uremic state on the development of malignancy. An experimental study in the rat. Am J Nephrol 1986; 6:363-8. [PMID: 3826134 DOI: 10.1159/000167192] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/07/2023]
Abstract
The effect of chronic uremia on the development of subcutaneously injected malignant tumoral cells was evaluated in 213 male Wistar AG rats made chronically uremic by simultaneous right nephrectomy and partial ligation of the left renal artery. The tumoral cells injected were stemming from a parental rhabdomyosarcoma (9-4/0) induced by intramuscular injection of 20 mg of colloidal nickel suspended in oil to a male Wistar rat. 54 sham-operated rats and 43 nonoperated animals served as control-groups. Renal function and tumoral growth were checked weekly up to the 60th postoperative day, at which time the surviving rats were sacrificed and submitted to autopsy. At day 15 after cell grafting, a tumoral lump could be felt by finger touch in 68% of the uremic rats, but in only 11% of the sham-operated and 14% of the nonoperated controls (p less than 0.0001). Throughout the study, the tumoral lumps which developed in the uremic animals were of significantly larger size than in the nonuremic controls. Pulmonary tumoral metastases were evidenced at autopsy in 95% of the uremic rats, but in only 50% of the sham-operated and in 54% of the nonoperated controls (p less than 0.005). These results indicate an apparently accelerating and amplifying effect of uremia on the development of a malignant tumor in the rat, for which a decrease in cell-mediated immunity associated with the uremic state still remains a questionable hypothesis.
Collapse
|
22
|
Poupon MF, Judde JG, Pot-Deprun J, Sweeney F, Lespinats G. Variable susceptibility to NK activity of cloned cell lines derived from a primary rat rhabdomyosarcoma: relationship to metastatic potential. Br J Cancer 1983; 48:75-82. [PMID: 6871080 PMCID: PMC2011409 DOI: 10.1038/bjc.1983.159] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/22/2023] Open
Abstract
In vitro cloned lines derived from a primary nickel-induced rat rhabdomyosarcoma exhibited diverse levels of susceptibility to spontaneous NK activity. The presence of NK target structures was revealed by competition assays on all cloned cell lines, and the NK susceptibility of the tumour lines varied according to their osmotic fragility. Tumour cell lines derived from metastatic lung nodules presented similar NK susceptibilities to cells originating from the primary tumour. However, cloned cell lines differed in their capacity to form lung colonies after i.v. injection, and in their potential for invading lungs after s.c. primary tumour development. No correlation was found between lung colonization potential and NK resistance. Studies of the correlation between metastatic potential and NK sensitivity revealed that (1) all the NK resistant tumour cells were highly metastatic; (2) NK susceptible tumour cells could be either highly or weakly metastatic. Therefore, highly metastatic tumour cells could be either resistant or susceptible to NK lysis. We conclude that the property of resistance to NK contributes to a high metastatic potential. However, other properties could counterbalance and finally prevail over NK susceptibility thus enabling NK susceptible cell lines to be also highly metastatic.
Collapse
|